Target intelligence / Profile preview

Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta (PDE6D) (PDE6D)

Target
PDE6D
Molecular classification
Other
01

Overview

Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta (PDE6D, also known as PDEδ) is a highly conserved, non-catalytic subunit of the PDE6 complex that functions primarily as a cytosolic trafficking chaperone for prenylated (farnesylated or geranylgeranylated) proteins. By binding the lipidated C-termini of cargo proteins within its hydrophobic pocket, PDE6D solubilizes them in the aqueous cytoplasm, facilitating their diffusion and proper localization to cellular membranes, such as the plasma membrane or primary cilia. Key cargo proteins of PDE6D include Ras family GTPases (such as KRAS, NRAS, and Rheb) and ciliary proteins (such as INPP5E).

In oncology, PDE6D has emerged as a prominent surrogate therapeutic target for KRAS-mutant cancers, such as pancreatic, colorectal, and lung cancers, where KRAS membrane localization is essential for oncogenic signaling. Small-molecule inhibitors (e.g., Deltarasin, Deltazinone, and Deltasonamides) and targeted protein degraders (PROTACs and molecular glues) have been developed to block the prenyl-binding pocket or induce PDE6D degradation, thereby mislocalizing KRAS to endomembranes and suppressing downstream MAPK/ERK and PI3K/AKT pathways. However, therapeutic challenges remain, including the broad cargo spectrum of PDE6D which can lead to off-target toxicities, and its critical role in ciliary trafficking, where genetic loss of function is associated with ciliopathies like Joubert syndrome.

Other names
PDE deltaPDEδGMP-PDE deltaProtein p17PDEDPhosphodiesterase 6DPhosphodiesterase type 6 delta
02

Mechanism of action

Inhibition of the prenyl-binding pocket, targeted protein degradation, molecular glue-mediated degradation, or stabilization of the KRAS-PDE6D complex

03

Biological functions

Signal transductionCell proliferationOther
04

Disease associations

CancerOther
05

Safety considerations

Off-target effects due to broad cargo spectrum affecting other prenylated proteinsRisk of ciliopathies such as Joubert syndrome due to disruption of ciliary traffickingLow solubility and poor pharmacokinetics of early inhibitorsPotential toxicity in non-malignant cells
06

Interacting drugs

Deltarasin

7 more in the full profile.

07

Biomarkers

KRAS mutation statusPDE6D expression levelERK phosphorylationAKT phosphorylationRAS membrane localization

Beyond the preview

Go deeper on Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta (PDE6D) (PDE6D).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta (PDE6D) (PDE6D).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call